



医渡科技 6 月通讯 | 2026 年

Yidu Tech Events in June 2026

集团亮点

Business Update

医渡科技 2026 财年业绩发布：全年盈利 7877 万元，下半年经营现金流转正

Yidu Tech Reports FY2026 Results: Annual Profit Reaches RMB 78.8 Million, with Positive Operating Cash Flow in the Second Half

医渡科技公布 2026 财年业绩报告并召开发布会对报告进行解读。报告期内公司首次实现全年盈利，年度利润达人民币 7876.6 万元，超出此前 5500 万至 7000 万元的盈利预告净利润区间上限；归母净利润达人民币 7270.9 万元，较预告对应的归母净利润区间上限 5600 万元高出约 30%。公司全年总收入同比增长 14.6% 达 8.2 亿元，经调整 EBITDA 同比增长超 4.6 倍至人民币 2.2 亿元。

盈利质量同步改善，整体毛利率较上年同期的 33.5% 进一步提升至 36.4%，下半年经营活动现金流净额实现转正，录得人民币 2930 万元，盈利能力进入上行通道。

增长动能方面，核心板块新增订单表现强劲。其中，AI for Medical 板块新增订单同比增长 22.3%，AI for Life Sciences 板块新增订单同比增长 42%，为后续收入增长提供了清晰的可预见性。

Yidu Tech announced its financial results for the fiscal year ended 31 March 2026 and held an earnings briefing to discuss the Company's performance. During the reporting period, the Company achieved its first full-year profit, reporting an annual profit of RMB 78.766 million, exceeding the upper end of its previously announced profit guidance of RMB 55 million to RMB 70 million. Profit attributable to equity shareholders reached RMB 72.709 million, approximately 30% above the upper end of the previously guided



range of RMB 56 million. Total revenue for the year increased 14.6% year on year to RMB 820 million, while adjusted EBITDA surged more than 4.6 times year on year to RMB 220 million.

The quality of earnings also continued to improve. Overall gross margin increased from 33.5% in the previous fiscal year to 36.4%, and net cash generated from operating activities turned positive in the second half of the year, reaching RMB 29.3 million, reflecting a meaningful improvement in the Company's profitability and cash generation.

Growth momentum remained strong across the Company's core businesses. New orders in the AI for Medical segment increased 22.3% year on year, while new orders in the AI for Life Sciences segment grew 42%, providing strong visibility into future revenue growth.

国家数据局局长刘烈宏调研医渡科技，关注医疗高质量数据集建设与应用

Liu Liehong, Head of the National Data Administration, Visits Yidu Tech to Explore High-Quality Healthcare Dataset Development and Applications


国家数据局党组书记、局长刘烈宏带队在北京市开展数据市场建设专题调研，实地走访了医渡科技，详细了解了医渡科技关于医疗健康数据资源开发利用、行业高质量数据集建设及人工智能应用落地等方面的情况。

调研现场，医渡科技联合创始人、首席执行官徐济铭代表公司向调研组汇报，展示了医渡科技在医疗健康行业高质量数据集建设，以及以高质量医疗健康数据赋能智能诊疗与药企研发等方面取得的积极进展。

Liu Liehong, Secretary of the Party Leadership Group and Head of the National Data Administration, led a delegation to Beijing to conduct a thematic study on data market development. During the visit, the delegation toured Yidu Tech to gain an in-depth understanding of the Company's efforts in healthcare data resource development and utilization, the construction of high-quality healthcare datasets, and the real-world

deployment of artificial intelligence.

During the visit, Xu Jiming, Co-founder and CEO of Yidu Tech, briefed the delegation on the Company's latest progress in developing high-quality healthcare datasets for the healthcare industry. He also highlighted how Yidu Tech is leveraging high-quality healthcare data to enable AI-powered clinical care and accelerate pharmaceutical research and development.



全国政协“推进全民健康数智化建设”专题调研组到访医渡科技

National Committee of the CPPCC Research Delegation Visits Yidu Tech to Explore Digital and Intelligent Healthcare Development

全国政协“推进全民健康数智化建设”专题调研组到访医渡科技开展调研。 医渡科技联合创始人、首席执行官徐济铭介绍了公司在医疗健康数据治理、垂域大模型研发及医疗 AI 产业化应用等方面的创新实践，重点展示了 YiduCore 医疗智能底座以及 AI 在临



床诊疗、医学科研、公共卫生和健康管理等场景的规模化落地成果。调研组对公司在医疗健康数据智能基础设施建设和医疗 AI 应用方面的实践给予肯定，并围绕医疗 AI 临床应用、数据安全合规、数据价值释放等议题进行了深入交流。

A research delegation from the National Committee of the Chinese People's Political Consultative Conference (CPPCC), conducting a special study on advancing digital and intelligent healthcare for all, visited Yidu Tech. During the visit, Xu Jiming, Co-founder and CEO of Yidu Tech, introduced the Company's innovations in healthcare data governance, the development of healthcare large language models, and the industrial application of medical AI. He highlighted YiduCore, the Company's proprietary AI healthcare foundation, as well as its large-scale deployment across clinical care, medical research, public health, and health management. The delegation spoke highly of Yidu Tech's achievements in building intelligent healthcare data infrastructure and advancing medical AI applications. The two sides also held in-depth discussions on topics including the clinical adoption of medical AI, data security and compliance, and unlocking the value of healthcare data.





董事长宫如璟出席 2026 夏季达沃斯论坛，分享医疗 AI 与数据基建实践

Chairlady Gong Yingying Shares Insights on Medical AI and Data Infrastructure at the 2026 Summer Davos Forum

医渡科技创始人、董事长宫如璟受邀出席世界经济论坛第十七届新领军者年会（2026 大连夏季达沃斯论坛）公开对话“新药研发提速，能否惠及更广”，围绕全球医药研发加速背景下的结构性变革，以及 AI 与医疗数据基建如何重构研发与临床体系分享实践与思考。她提出，医疗 AI 的核心竞争力不在模型，而在高质量数据池。只有将原始数据转化为可追溯、可验证的临床证据，才能构建可信、可控、符合安全边界的 AI 智能体，支撑新药研发提质增效。

论坛期间，宫如璟受邀参加了总理与工商界代表座谈会，并接受了 CCTV、CGTN 等多家媒体访谈，还参与了夏季达沃斯全新播客栏目 Davos On Air，与《彭博商业周刊》资深财经撰稿人 Stacey Vanek Smith 展开一对一对话，围绕医疗 AI 与产业创新等前沿议题进行交流，向全球分享中国医疗 AI 创新实践。

Gong Yingying, Founder and Chairlady of Yidu Tech, was invited to speak at the open forum "Faster Drugs, Better Access?" during the 17th Annual Meeting of the New Champions (Summer Davos 2026) hosted by the World Economic Forum. She shared Yidu Tech's experience and perspectives on the structural transformation of global drug development, and how AI and healthcare data infrastructure are reshaping pharmaceutical R&D and clinical practice. Gong emphasized that the true competitive advantage of medical AI lies not in the model itself, but in the quality of the underlying data. Only by transforming raw data into traceable and verifiable clinical evidence can the industry build trustworthy, controllable AI agents that operate within clear safety boundaries and effectively accelerate innovation in drug development.

During the forum, Gong was also invited to attend the Special Dialogue with Premier Li Qiang. She gave interviews to leading media outlets including CCTV and CGTN, and joined the inaugural Davos On Air podcast, where she sat down for a one-on-one conversation with Stacey Vanek Smith, Senior Writer at Bloomberg Businessweek.



Their discussion explored the future of medical AI, industrial innovation, and China's experience in advancing AI-driven healthcare.



医渡科技亮相智源大会，以“可循证溯源智能体体系”重塑医疗 AI 落地范式

Yidu Tech Showcases Evidence-Based, Traceable AI Agent Framework at BAAI Conference, Advancing the Next Stage of Medical AI

第八届北京智源大会在北京圆满召开。本届大会延续“AI 年度盛会”的基因，汇聚 2 位图灵奖得主、8 位院士、30 位 30 岁以下青年科学家、40 余位 AI 企业 CEO 及创始人，实现了大规模跨国界、跨领域的集中同台，线下参会人数突破万人。其中，智能体技术成为核心关注方向之一。

医渡科技受邀出席，公司技术创新副总裁、AI 架构师李林峰博士发表题为《可循证溯源的医疗智能体开发与应用实践》的主题演讲，系统展示了医渡科技围绕医疗智能体构建的完整技术体系与临床落地路径，进一步阐释医疗 AI 从“模型能力驱动”向“系统级真实应用能力”演进的产业趋势。



The 8th Beijing Academy of Artificial Intelligence (BAAI) Conference was successfully held in Beijing. Continuing its reputation as one of the year's premier AI events, the conference brought together two Turing Award laureates, eight academicians, 30 outstanding scientists under the age of 30, and more than 40 AI company CEOs and founders, attracting over 10,000 in-person attendees. AI agents emerged as one of the conference's central themes.

Yidu Tech was invited to participate in the event, where Li Linfeng, Vice President of Technology Innovation and AI Architect, delivered a keynote titled "Developing Evidence-Based, Traceable Medical AI Agents: From Architecture to Real-World Practice." In his presentation, he showcased Yidu Tech's comprehensive technical framework for building medical AI agents and the pathway to large-scale clinical deployment, highlighting the industry's evolution from model-centric capabilities toward system-level, real-world AI applications.





医渡科技助力北京协和打造专科专病智能体矩阵，亮相国家 AI 应用中试基地成果发布会

Yidu Tech Supports PUMCH in Launching Specialty AI Agent Matrix at National AI Pilot Base Showcase

在医疗领域国家人工智能应用中试基地阶段性成果发布会上，北京协和医院携专科专病 AI 智能体矩阵重磅亮相。作为北京市医疗领域国家人工智能应用中试基地核心生态伙伴，医渡科技深度参与平台建设 with 场景创新，为北京协和医院提供 Dr.Copilot 临床助手平台作为统一底座与调度引擎，支撑专科专病智能体矩阵建设，推动可溯源病历生成、循证治疗方案推荐等智能体落地临床，持续探索医疗 AI 规模化应用新路径。

At the milestone achievements event for the National Artificial Intelligence Pilot Base for Healthcare Applications, Peking Union Medical College Hospital (PUMCH) unveiled its new matrix of specialty- and disease-specific AI agents. As a core ecosystem partner of the Beijing National Artificial Intelligence Pilot Base for Healthcare Applications, Yidu Tech played a key role in both platform development and application innovation. The Company provided its Dr. Copilot clinical assistant platform as the unified foundation and orchestration engine for the AI agent matrix, enabling the deployment of AI agents for use cases such as traceable medical record generation and evidence-based treatment recommendations in clinical practice. The collaboration continues to explore new pathways for the large-scale adoption of medical AI.



辉瑞中国到访医渡科技，共探 AI 赋能医疗创新合作

Pfizer China Visits Yidu Tech to Explore AI-Driven Healthcare Innovation

辉瑞中国炎症免疫事业部和广阔市场事业部团队到访医渡科技北京总部，与医渡科技联合创始人、首席执行官徐济铭及核心管理团队开展交流。双方围绕 AI 赋能临床科研、真实世界研究、数据洞察、患者管理及县域肿瘤防治等领域深入探讨，进一步凝聚长期战略合作共识，携手推动 AI 技术与医药创新深度融合，助力医疗健康高质量发展。

Teams from Pfizer China's Inflammation & Immunology Business Unit and Broad Market Business Unit visited Yidu Tech's Beijing headquarters for discussions with Xu Jiming, Co-founder and CEO of Yidu Tech, and the Company's senior management team. The two sides held in-depth exchanges on opportunities for AI-enabled clinical research, real-world evidence, data-driven insights, patient management, and oncology prevention and treatment in county-level healthcare systems. They also reinforced their shared commitment to a long-term strategic partnership, with the goal



of accelerating the integration of AI and pharmaceutical innovation to advance high-quality healthcare development.



沙特代表团到访医渡科技，共探中沙数字医疗与人工智能合作新机遇

Saudi Delegation Visits Yidu Tech to Explore New Opportunities in Digital Health and AI Collaboration

沙特产业与投资代表团到访医渡科技北京总部，就数字医疗发展、智慧医院建设、医疗数据智能化应用及海外项目合作等议题开展深入交流。医渡科技分享了在医疗大数据治理、AI 临床应用、真实世界研究及公共卫生数字化等领域的技术能力，并介绍了文莱、新加坡等国际项目实践。双方围绕中沙数字医疗合作、AI 医疗应用及产业生态共建达成积极共识，为深化中东市场合作、推动跨境数字医疗项目落地奠定基础。

A Saudi industry and investment delegation visited Yidu Tech's Beijing headquarters for in-depth discussions on digital health development, smart hospital initiatives, intelligent healthcare data applications, and international project collaboration. During the meeting, Yidu Tech showcased its expertise in healthcare data governance, AI-

powered clinical applications, real-world evidence, and digital public health, while also sharing international project experience in Brunei Darussalam and Singapore. The two sides reached a broad consensus on strengthening China–Saudi collaboration in digital health, advancing AI applications in healthcare, and fostering a collaborative industry ecosystem, laying the groundwork for deeper cooperation in the Middle East and the implementation of cross-border digital health initiatives.



医渡科技参加第四届链博会，探讨 AI 赋能药械研发与产业协同

Yidu Tech Joins the 4th China International Supply Chain Expo to Discuss AI-Driven Drug and Medical Device Innovation

在第四届中国国际供应链促进博览会“人工智能赋能医疗健康和生物制造产业链专题活动”上，医渡科技高级副总裁、科研业务线总经理黄楠博士受邀参加“AI 赋能创新药械研发应用：政策护航与产业协同”圆桌论坛。会上，医渡科技提出以“数据供应链”重构药械研发协作模式，分享了覆盖“全院—专科—联盟—院外”的智能科研生态体系，



以及基于科研专病库的高质量数据集解决方案。依托与全国上百家重点医院及多个区域医疗中心的深度合作，医渡科技持续推动高质量数据集建设与流通，为临床研究、AI 模型训练和创新药械研发提供底层支撑，助力行业从单点创新迈向全链协同。

At the AI Empowering Healthcare and Biomanufacturing Supply Chains forum during the 4th China International Supply Chain Expo (CISCE), Huang Nan, Senior Vice President of Yidu Tech and General Manager of the Research Business Unit, was invited to participate in the roundtable discussion, "AI Empowering Innovative Drug and Medical Device R&D: Policy Support and Industry Collaboration."

During the discussion, Yidu Tech proposed reimagining collaboration in drug and medical device R&D through a "data supply chain" approach. The Company shared its intelligent research ecosystem spanning hospital-wide, specialty, alliance, and out-of-hospital scenarios, along with its high-quality dataset solution built on disease-specific research databases. Leveraging deep collaborations with more than 100 leading hospitals and multiple regional medical centers nationwide, Yidu Tech continues to advance the development and circulation of high-quality healthcare datasets. These efforts provide a robust data foundation for clinical research, AI model training, and innovative drug and medical device development, helping the industry evolve from isolated innovation toward end-to-end ecosystem collaboration.



医渡科技出席 Vision China，以高质量数据集解决方案赋能专病库一库多用

Yidu Tech Showcases High-Quality Dataset Solutions for Multi-Purpose Disease Registries at Vision China

医渡科技受邀参加 Vision China 视觉健康创新发展国际会议。公司高级副总裁、科研业务线总经理黄楠博士围绕高质量数据集赋能医疗 AI 发展发表主题演讲，提出高质量数据集是医疗 AI 落地和临床科研成果转化的关键基础，并分享了医渡科技基于科研专病库构建高质量数据集、支撑临床决策、科研创新和药物研发的实践成果，以及在肿瘤、眼科、老年认知等领域推动 AI 规模化应用的创新案例。

Yidu Tech was invited to participate in the Vision China International Conference on Innovation in Vision Health. At the conference, Dr. Huang Nan, Senior Vice President and General Manager of the Research Business Unit, delivered a keynote presentation on how high-quality datasets are driving the development of medical AI. Dr. Huang highlighted that high-quality datasets are the foundation for translating medical AI into clinical practice and accelerating clinical research. She also shared Yidu Tech's approach to building high-quality datasets from disease registries to support clinical



decision-making, research innovation, and drug development. In addition, she showcased the company's AI application cases in oncology, ophthalmology, and cognitive health, demonstrating how high-quality datasets are enabling scalable AI adoption across multiple disease areas.



医渡科技参加 2026 APEC 中小企业工商论坛，以数字健康技术深化亚太合作

Yidu Tech Participates in the 2026 APEC SME Business Forum, Advancing Asia-Pacific Collaboration Through Digital Health Technologies

2026 年 APEC(亚太经济合作组织)中小企业工商论坛在深圳开幕，本届论坛以“数智赋能，开放创新，合作共赢”为主题，汇聚 APEC 各成员经济体政府代表、院士专家及头部企业，共同探讨亚太中小企业数智转型与开放合作新路径。医渡科技作为中国医疗人工智能领域的代表企业受邀参会，公司政务副总裁袁启龙在人工智能赋能亚太中小企业产业发展论坛上发表演讲，围绕亚太区域健康发展差距的共性挑战，系统分享人工智能技术弥合健康鸿沟的落地实践与可行路径。



Yidu Tech participated in the 2026 APEC (Asia-Pacific Economic Cooperation) SME Business Forum, held in Shenzhen. Under the theme "Digital Intelligence, Open Innovation, and Win-Win Cooperation," the forum brought together government representatives, leading academics, and industry leaders from APEC member economies to explore new pathways for the digital transformation and cross-border collaboration of SMEs across the Asia-Pacific region. As a representative of China's medical AI sector, Yidu Tech was invited to join the forum. Yuan Qilong, Vice President of Government Affairs, delivered a keynote speech at the AI Empowering Asia-Pacific SME Development Forum. Addressing the shared challenges of health disparities across the region, he presented Yidu Tech's practical experience and actionable approaches to leveraging artificial intelligence to bridge healthcare gaps and advance more equitable health outcomes across the Asia-Pacific.



医渡科技受邀参加浙江省政府座谈会，共谋京浙医疗 AI 协同发展新篇章

Yidu Tech Invited to Zhejiang Provincial Government Symposium to Advance Beijing–Zhejiang Collaboration in Medical AI

由中关村高科技创新企业（院士团队）组成的考察团赴浙江调研交流，浙江省政府召开座谈会，副省长胡伟出席并讲话。医渡科技作为医疗人工智能企业代表受邀参会，并分



享公司在医疗 AI、城市健康治理、智慧医院建设及医学科研等领域的实践成果，重点介绍了在宁波、台州、浙江省人民医院、温州医科大学附属眼视光医院、温州市中心医院等地的落地案例。未来，公司将持续深化与浙江省合作，推动医疗 AI 技术创新、临床转化与产业应用，加快医疗人工智能规模化落地。

Yidu Tech was invited to participate in a symposium hosted by the Zhejiang Provincial Government during a research and exchange visit by a delegation of leading Zhongguancun high-tech enterprises and academician-led innovation teams. The meeting was attended by Vice Governor Hu Wei, who delivered opening remarks. As a representative of the medical AI industry, Yidu Tech shared its latest practices in medical AI, urban health governance, smart hospital development, and clinical research. The company also highlighted successful implementations across Zhejiang Province, including projects in Ningbo, Taizhou, Zhejiang Provincial People's Hospital, the Eye Hospital of Wenzhou Medical University, and Wenzhou Central Hospital. Looking ahead, Yidu Tech will continue to deepen its collaboration with Zhejiang Province, accelerating innovation in medical AI, advancing clinical translation, and expanding real-world adoption of AI technologies across the healthcare ecosystem.

医渡科技亮相腾讯云 AI 产业应用大会，提出医疗 AI 落地三大关键

Yidu Tech Showcases Medical AI Best Practices at Tencent Cloud AI Industry Applications Summit, Highlighting Three Keys to Real-World Adoption

以“Agent 进场，效能生长”为主题的 2026 腾讯云 AI 产业应用大会召开。医渡科技受邀出席本次大会的智慧医疗专场，公司技术创新副总裁、AI 架构师李林峰博士参与圆桌对话环节，分享医渡科技基于“数据中台+AI 中台”打造全场景 AI 驱动解决方案的实践成果，并围绕医疗 AI 落地提出“嵌入 workflow、智能体协同、可溯源可信”三大关键观点，展示了公司在临床诊疗、医学科研、医院运营及患者服务等场景的创新实践与规模化应用经验。



Yidu Tech was invited to participate in the 2026 Tencent Cloud AI Industry Applications Summit, held under the theme "Agents in Action, Intelligence in Growth." At the Smart Healthcare Forum, Dr. Li Linfeng, Vice President of Technology Innovation and AI Architect at Yidu Tech, joined a panel discussion to share the company's experience in building end-to-end AI-driven healthcare solutions powered by its Data Middleware Platform + AI Middleware Platform architecture. Drawing on Yidu Tech's real-world deployment experience, Dr. Li outlined three key principles for successful medical AI adoption: embedding AI into clinical workflows, enabling collaboration among AI agents, and ensuring traceability and trustworthiness. He also showcased the company's large-scale AI applications across clinical care, medical research, hospital operations, and patient services, demonstrating how AI can deliver measurable value throughout the healthcare ecosystem.





业务进展

Business Progress

医渡科技与中大医院达成战略合作，共推 AI 肝癌诊疗普惠全球

Yidu Tech and Zhongda Hospital Forge Strategic Partnership to Expand AI-Powered Liver Cancer Care Worldwide

继与东南大学附属中大医院滕皋军院士团队联合打造“小肝人”之后，双方合作再上新台阶。近日苏州召开的 ISMIO 2026 联合第 20 届 APSCVIR 大会上，医渡科技与东南大学附属中大医院正式签署战略合作协议，不仅推动中国 AI 肝癌诊疗方案普惠基层，更将“中国智慧”推向亚太及全球。与此同时，“小肝人”——AI 赋能肝病全周期临床解决方案在大会开幕式亮相，开启肝癌 AI 诊疗普惠新篇章。

Following the successful launch of "Xiao Gan Ren" in collaboration with the academician team led by Academician Teng Gaojun at Zhongda Hospital, Southeast University, Yidu Tech has taken its partnership with the hospital to a new level. At the ISMIO 2026 Annual Meeting, held jointly with the 20th APSCVIR Congress in Suzhou, Yidu Tech and Zhongda Hospital of Southeast University officially signed a strategic cooperation agreement. The partnership aims not only to bring AI-powered liver cancer diagnosis and treatment to primary healthcare providers across China, but also to extend these innovative solutions to the Asia-Pacific region and beyond. At the conference opening ceremony, "Xiao Gan Ren"—an AI-powered, end-to-end clinical solution for liver disease management—was officially unveiled, marking a new milestone in making AI-enabled liver cancer care more accessible and widely available.



医渡科技发布 EYWA 6.0 新一代数智中心，重构医院 AI 底座

Yidu Tech Unveils EYWA 6.0 Next-Generation Digital Intelligence Center to Reinvent the AI Foundation for Hospitals

在山东省研究型医院学会信息化与互联网医疗分会第五届学术会议上，医渡科技发布 EYWA 6.0 新一代数智中心。该方案围绕高质量数据资产生产、全域数据编织、医学知识融合和模型场景赋能，帮助医院构建 AI-ready 数智基础设施，支撑大模型训练、智能体开发及多场景应用落地，推动医院数智化建设从项目建设迈向持续运营。

At the 5th Academic Conference of the Information Technology and Internet Healthcare Committee of the Shandong Research Hospital Association, Yidu Tech unveiled EYWA 6.0, its next-generation Digital Intelligence Center. Designed to help hospitals build AI-ready digital infrastructure, EYWA 6.0 integrates high-quality data asset generation, enterprise-wide data fabric, medical knowledge integration, and model-driven application enablement. The platform provides a robust foundation for large language model training, AI agent development, and the deployment of AI across diverse clinical and operational scenarios. By shifting the focus from one-off IT projects

to continuous digital operations, EYWA 6.0 supports hospitals in building a sustainable, scalable AI ecosystem and accelerating their digital transformation.



医渡科技推出新药立项结构化评估体系，助力药企实现价值驱动决策

Yidu Tech Launches a Structured Drug Asset Evaluation Framework to Enable Value-Driven R&D Decisions

医渡科技围绕创新药立项中的“临床真实需求是否重要、是否值得投入”这一核心命题，发布以“未满足临床需求”为核心的结构化评估体系。该体系通过疾病机制梳理、现有治疗短板分析、目标患者群体评估、TPP 关键阈值设定、医生诊疗与替代意愿调研、市场空间及准入可行性预判等多维度交叉验证，帮助药企在立项早期系统量化项目差异化价值与临床转化潜力。依托医学团队、案头研究和一手临床调研能力，医渡科技为新药研发提供可衡量、可验证、可决策的科学依据，推动立项决策从“经验驱动”转向“价值验证驱动”。



Yidu Tech has introduced a structured evaluation framework centered on unmet clinical needs, addressing one of the most critical questions in innovative drug development: Does a clinical need truly matter, and is it worth investing in? The framework systematically assesses the differentiated value and clinical translation potential of drug candidates at the earliest stages of development through multidimensional analysis, including disease mechanism review, evaluation of current treatment gaps, target patient population assessment, Target Product Profile (TPP) threshold definition, physician treatment and switching preference research, and market opportunity and access feasibility analysis. Leveraging its multidisciplinary medical team, comprehensive desk research, and primary clinical insights, Yidu Tech provides biopharmaceutical companies with measurable, evidence-based, and decision-ready intelligence. The framework helps shift early-stage R&D decision-making from experience-driven judgment to value-driven validation, enabling more informed and strategic investment decisions.

集团荣誉

Honors of Yidu Tech

医渡科技医疗智能体实践入选行业白皮书，多家三甲医院联合案例获收录

Yidu Tech's Medical AI Agent Innovations Featured in Industry White Paper, with Joint Projects from Leading Hospitals Recognized

在“智源齐说·大模型应用大会”上，《2026 医疗智能体应用发展白皮书》正式发布。医渡科技凭借在医疗智能体领域成熟的落地实践，其 AI 中台、医渡智循等产品以及联合多家三甲医院打造的可溯源病历生成智能体、肿瘤分期智能体案例被收录于白皮书，获



得行业高度认可。医渡科技技术创新副总裁、AI 架构师李林峰博士出席白皮书发布仪式，并在会上发表《智构中台·慧诊临床：医疗智能体从开发到临床应用》主题演讲。

At the Zhiyuan Qishuo: Large Language Model Applications Conference, the 2026 White Paper on Medical AI Agent Applications was officially released. Yidu Tech's mature real-world implementations in medical AI agents were recognized in the white paper, including its AI Middleware Platform, Yidu Evidence, and jointly developed solutions with leading Class III hospitals, such as a traceable medical record generation agent and an oncology staging agent. The inclusion highlights the industry's recognition of Yidu Tech's capabilities in advancing trustworthy and clinically deployable AI. Dr. Li Linfeng, Vice President of Technology Innovation and AI Architect at Yidu Tech, attended the white paper launch ceremony and delivered a keynote presentation titled "Building Intelligent Middleware, Empowering Clinical Care: From Medical AI Agent Development to Clinical Deployment."





医渡科技智能体实践获评 2026 全国企业新质生产力赋能典型案例

Yidu Tech Recognized as a 2026 National Best Practice for Advancing New Quality Productive Forces Through AI

由德本咨询、中国科学院《互联网周刊》、eNet 研究院联合发起评选的“2026 全国企业新质生产力赋能典型案例”正式揭晓。医渡科技凭借“可循证溯源临床智能体矩阵在三甲医院大规模落地实践”案例成功获评，并且是榜单中唯一的医疗领域案例，体现了行业对其深耕医疗垂直 AI、推动医疗智能化变革实践的高度认可。

Yidu Tech has been named one of the 2026 National Best Practice Cases for Empowering New Quality Productive Forces, an initiative jointly organized by Deben Consulting, Internet Weekly of the Chinese Academy of Sciences, and the eNet Research Institute. The company was recognized for its large-scale deployment of an evidence-based, traceable clinical AI agent ecosystem across leading Class III hospitals. Notably, Yidu Tech's submission was the only healthcare case selected for the list, underscoring the industry's recognition of its leadership in vertical medical AI and its contributions to accelerating intelligent transformation across healthcare.





医渡科技凭核心产品医渡智循斩获 2026 临床级循证智能体领航奖

Yidu Tech Wins the 2026 Clinical-Grade Evidence-Based AI Agent Leadership Award for Yidu Evidence

由德本咨询、中国科学院《互联网周刊》、eNet 研究院联合发起的 2026（第八届）创新发展论坛金 i 奖正式揭晓榜单。医渡科技凭借自研临床级循证智能体产品医渡智循，在 AI 医疗赛道一众参评企业中脱颖而出，拿下重磅奖项“2026 临床级循证智能体领航奖”，行业对其循证技术路线与临床落地价值给予高度肯定。

At the 2026 (8th) Innovation Development Forum Golden i Awards, jointly organized by Deben Consulting, Internet Weekly of the Chinese Academy of Sciences, and the eNet Research Institute, Yidu Tech's proprietary clinical-grade evidence-based AI agent, Yidu Evidence, was honored with the 2026 Clinical-Grade Evidence-Based AI Agent Leadership Award. Standing out among a competitive field of AI healthcare innovators, Yidu Evidence was recognized for its evidence-based technology approach and proven clinical value, reflecting strong industry recognition of Yidu Tech's leadership in translating trustworthy AI into real-world clinical practice.





投资者交流

Investor Communication

医渡科技 CFO 封晓瑛做客《投资人去哪儿》：解读盈利拐点与长期价值

Yidu Tech CFO Feng Xiaoying on *Where Investors Go*: Discussing the Company's Profitability Inflection Point and Long-Term Growth

医渡科技执行董事、首席财务官封晓瑛女士做客由 E 药经理人主办的《投资人去哪儿》第八季第三期，围绕“AI 医疗——商业化兑现与价值重估”主题，从公司首度实现全年盈利、商业模式、技术壁垒、行业估值、全球化布局及未来战略等多个维度展开深度分享，全面拆解 AI 医疗头部企业的成长逻辑与行业发展趋势。

关于医渡科技的核心价值与成长逻辑，封晓瑛表示，公司用十余年打造了“医院 AI 操作系统”，通过深度嵌入医生工作全流程，实现数据、算法与场景的持续迭代，打造最懂疾病的 AI，持续提升医疗供给侧效率与质量。随着商业模式持续跑通、飞轮效应不断释放，公司长期成长价值正进一步显现。

Yidu Tech's Executive Director and Chief Financial Officer, Feng Xiaoying, joined Season 8, Episode 3 of *Where Investors Go*, a program hosted by E Drug Manager, for an in-depth discussion on "AI in Healthcare: Commercialization and Value Revaluation." During the interview, Feng shared insights into Yidu Tech's first full year of profitability, its business model, technology moat, industry valuation, global expansion strategy, and long-term vision, offering a comprehensive perspective on the company's growth trajectory and the evolving medical AI landscape.

Discussing Yidu Tech's core value proposition, Feng noted that the company has spent more than a decade building what it calls an AI operating system for hospitals. By deeply embedding AI throughout physicians' workflows, Yidu Tech has created a continuous feedback loop between data, algorithms, and real-world clinical scenarios to develop AI that truly understands disease. As its business model continues to scale



and its flywheel gains momentum, the company's long-term growth potential is becoming increasingly evident.